OS and RFS from randomization for patients with NPM1^mutat AML diagnosis by MRD status at baseline (after chemotherapy) and randomized treatment arm. (A) OS. (B) RFS. MRD was determined centrally at study entry by multiparameter flow cytometry using a different-from-normal method with a 0.1% positivity threshold.